Late Breaking Abstract - Clinical remission with dupilumab in children with uncontrolled, moderate-to-severe, type 2 asthma
Bibliographic record
Abstract
INTRODUCTION: Dupilumab, a human monoclonal antibody, blocks signaling of interleukins 4/13, central drivers of type 2 inflammation. In phase 3 VOYAGE ( NCT02948959 ), dupilumab reduced severe exacerbations and improved lung function and asthma control vs placebo in children (6 to 11 years) with moderate-to-severe type 2 asthma (baseline blood eosinophil count ≥150 cells/µL or fractional exhaled nitric oxide ≥20 ppb). Here, we assessed the effect of dupilumab in achieving on-treatment clinical remission, a proposed composite endpoint, in children in VOYAGE. METHODS: We assessed proportions of children achieving on-treatment clinical remission (no exacerbations/oral corticosteroid use; z-score >−1.64 for both pre-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio and pre-bronchodilator FEV1; and 5-item Asthma Control Questionnaire (ACQ-5) score <0.75.) RESULTS: 236 children received add-on dupilumab and 114 placebo. At baseline, no children in either treatment group met the requirements for remission using ACQ-5 <0.75. A significantly higher proportion of children receiving dupilumab vs placebo achieved clinical remission at Week 52 (41.9% vs 23.7%; P=0.0008; Figure). CONCLUSION: Compared with placebo, dupilumab significantly increased the proportion of patients with uncontrolled, moderate-to-severe type 2 asthma who achieved on-treatment clinical asthma remission at Week 52. erj;64/suppl_68/RCT3719/F1 F1 F1
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".